In 2024, QUARTET continued to grow and support the delivery of high-quality radiotherapy across trials from SIOP Europe Clinical Trial Study Groups such as the Brain Tumour Group, EpSSg, Euro-Ewing Consortium, RT-SG and SIOPEN. As a result of the ever-growing network and portfolio of projects, the organization of QUARTET has been reviewed and in 2024 the QUARTET Research Leads Council was launched, as well as some exciting new working groups for particle therapy and adaptive radiotherapy.
Site RTQA approvals and individual case reviews of radiotherapy treatment plans for patients in FaR-RMS (EpSSG), HRMB (SIOP Europe Brain Tumour Group), HR-NBL2 (SIOPEN) and LINES (SIOPEN) are ongoing - with around 161 site approvals across 24 countries and over 700 patient reviews completed. We are currently working with the radiotherapy committees of the trials and the European Clinical Trial Study Groups to review common causes of error, and to produce additional resources and guideline updates to better support centers in delivering high quality radiotherapy for children and adolescents.
On October 7, 2024, QUARTET held its annual meeting in Brussels. We were pleased to have a good turnout of sponsor representatives, reviewers, study directors, fellows and research collaborators attending the meeting. We discussed all ongoing and planned trials, the latest progress on research projects, new activities and proposals, and future directions for QUARTET.
As always, more information can be found on the QUARTET website, including an updated list and links to all our publications and other outputs of interest.